

PhytoIntelligence 1.8

Finalized Evidence-Based Research Proposal

Project D021.1: Multi-Pathway Network Pharmacology for GBM

Lead Architect: Marie-Soleil Seshat Landry

Affiliation: Landry Industries | Scientibots

Target System: Glioblastoma Multiforme (GBM)

Abstract

This finalized proposal presents the biochemical rationale for the D021.1 formulation. Each component is selected based on its C_d score and supported by contemporary scientific literature (2021–2025). The protocol utilizes Borneol-mediated BBB opening and Berberine-mediated efflux inhibition to ensure that the primary flavonol matrix (Quercetin/Cannflavins) reaches therapeutic concentrations in the CNS.

December 26, 2025

1 Formulation Matrix & Scientific Evidence

The PhytoIntelligence 1.8 Engine has verified the following components against the most recent clinical and preclinical datasets.

Component	Mechanism of Action (MOA)	Ratio	Scientific DOI / Reference
Quercetin	Dual inhibition of Wnt/ β -Catenin and Akt/NF- κ B; induces apoptosis via membrane-TRAIL.	40%	10.1016/j.phymed.2023.154933
Naringin	Downregulation of MMP-2/9; inhibits FAK activity and tumor neoangiogenesis.	25%	10.1186/s40360-020-00426-1
Cannflavin B	Robust anti-migratory and anti-invasive action; limits GBM cell viability.	20%	10.1101/2025.07.02.662823
L-Borneol	Transient disruption of BBB; downregulates ZO-1 and F-actin tight junctions.	10%	10.1080/13880209.2016.1199044
Berberine	Induction of autophagy via AMPK/mTOR/ULK1; P-gp efflux inhibition.	5%	10.18632/oncotarget.14959

2 Specific Mechanism Validations

2.1 Barrier Penetration (The Borneol Node)

Traditional GBM phytotherapy fails because bioactive concentrations in the CSF remain below the IC_{50} . L-Borneol is included to act as a “messenger drug.” Per *PubMed 28471848*, oral administration of L-Borneol induces transient BBB disruption within 20 minutes, significantly increasing the concentration of adjunct molecules in peritumoral tissue.

2.2 Resistance Reversal (The Naringin/Berberine Node)

Glioblastomas often exhibit high MGMT expression, leading to Temozolomide resistance. Quercetin and Naringin have been shown to epigenetically modulate MGMT ([PhytoMedicine, 2023](#)). Berberine serves as a critical 5% stabilizer, preventing the “revolving door” effect where the BBB transporters (P-gp) pump flavonoids back into the systemic circulation.

2.3 Neuro-Targeting (The Cannflavin Node)

Recent preclinical data (*bioRxiv 2025.07.02.662823*) highlights that Cannflavin B, a uniquely prenylated flavonoid from *Cannabis sativa*, exhibits superior anti-invasive properties compared to non-prenylated flavones, making it essential for targeting the “migratory front” of GBM.

3 Compliance & Framework Alignment

This proposal is locked under the **PhytoIntelligence 1.8 Protocol**. All supply chain logistics for the extracted materials must follow the ESG-Sourcing guidelines (Section 13) to ensure molecular purity and UDOR (Universal Declaration of Organic Rights) compliance.

4 Conclusion

The D021.1 suite is the first predictive oncology formulation to address the "Barrier-Metabolism-Resistance" triad using a network of synergistic phytochemicals. Experimental deployment via Digital Human Twin is the next mandatory phase.